Search

everythinglearnresearchcommunity

for

Search:↓

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

New treatments for Alopecia Areata show promise but need to be more effective and affordable.

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.

Skin conditions can signal heart issues, highlighting the need for integrated care.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.

New treatments for hair loss show promise but need more research to confirm safety and effectiveness.

Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

JAK inhibitors and combination therapies show promise for treating severe alopecia areata.

Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.

Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Transforming skin disease treatment requires new strategies, better drug models, and patient-focused research.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

JAK inhibitors may reverse early hair loss, but prolonged inflammation can cause permanent hair loss.

Aging reduces skin cell renewal and defense against germs due to TGFbeta, but blocking TGFbeta could help restore these functions.

Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.